J&J's vaccine uses a technology based on a modified version of an adenovirus to spur immunity in recipients, while the Moderna and Pfizer-BioNTech vaccines use mRNA technology.
The CDC's Advisory Committee on Immunization practices was expected to vote on the issue on Thursday, after a subcommittee said it supported making the"preferential recommendation". Cases of thrombosis with thrombocytopenia syndrome, which involves blood clots accompanied by a low level of platelets, have previously been reported in recipients of the J&J vaccine.
The CDC said that the rate of such incidents is higher than previously estimated, both in women and men. At least nine people have died following the blood clotting incidents in the United States, the CDC has said.
莫德納疫苗不就是mRNA疫苗嗎？
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer says COVID-19 pill near 90% protective against hospitalization, deathNEW YORK (Reuters) -Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus. The U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo, based on interim results in around 1,200 people. Nobody in the trial who received the Pfizer treatment died, compared with 12 deaths among placebo recipients. The Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms.
Source: YahooSG - 🏆 3. / 71 Read more »
India stuck with COVID-19 vaccines it can't exportIndia is struggling to export its surplus of COVID-19 vaccines as logistical hurdles delay their use in many countries despite low levels of inoculation, vaccine producer the Serum Institute of India (SII) and a government official said on Tuesday. The SII, the world's biggest vaccine maker that produces the AstraZeneca, Novavax and Sputnik COVID-19 shots, has already announced plans to temporarily halve output of the AstraZeneca drug until more orders came, including possibly through boosters. 'All over the world, there is enough supply but it is getting the jabs in arms, which will take some time,' SII Chief Executive Adar Poonawalla told a virtual conference organised by the Confederation of India Industry. Top Indian health official Vinod Kumar Paul told the same event that current global COVID-19 vaccine production was enough to reach the nearly 3.6 billion who have yet to receive a shot.
Source: YahooSG - 🏆 3. / 71 Read more »